Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Molecular therapy for polyQ disorders: from bench to clinical trials

João de Sousa-Lourenço,Ana C. Silva,Luís Pereira de Almeida,Rui J. Nobre

Trends in Molecular Medicine（2024）

Cited 0|Views15
No score
Abstract
Polyglutamine (polyQ) disorders are monogenic neurodegenerative disorders. Currently, no therapies are available for this complex group of disorders. Here, we aim to provide an overview of recent promising preclinical studies and the ongoing clinical trials focusing on molecular therapies for polyQ disorders.
More
Translated text
Key words
polyQ disorders,molecular therapy,clinical trials,Huntington’s disease,spinocerebellar ataxia type 1,spinocerebellar ataxia type 3
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined